Chemotherapeutic Agents for Urologic Oncology

作者: Hendrik Van Poppel , Filip Ameye

DOI: 10.1007/978-1-84882-034-0_13

关键词:

摘要: The main goal of chemotherapy is to cure cancer by killing the neoplastic cells. To keep from metastasizing, may be used in combination with other treatments, such as surgery and radiotherapy. In widespread, fast-growing cancers, reduces cellular proliferation, eases symptoms, improves quality life. When it employed after primary tumor has been treated some modality, called adjuvant chemotherapy. Sometimes neoadjuvant employed, which refers initial use patients localized order reduce burden, there rendering local therapy (surgery or radiotherapy) more effective. A common procedure human that parallel sequential several different antineoplastic agents enhance their effectiveness. Combining targeted therapies an investigational approach under development. This chapter presents a comprehensive overview chemotherapeutics treatment urologic malignancies.

参考文章(45)
Cora N. Sternberg, Alan Yagoda, Howard I. Scher, Robin C. Watson, Harry W. Herr, Michael J. Morse, Pramod C. Sogani, E. Darracott Vaughan, Neil Bander, Lora R. Weiselberg, Nancy Geller, Phyllis S. Hollander, Roberta Lipperman, William R. Fair, Willet F. Whitmore, M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. The Journal of Urology. ,vol. 139, pp. 461- 469 ,(1988) , 10.1016/S0022-5347(17)42494-3
Michael Huncharek, Jean-Francois Geschwind, Bart Witherspoon, Ronald McGarry, David Adcock, Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. Journal of Clinical Epidemiology. ,vol. 53, pp. 676- 680 ,(2000) , 10.1016/S0895-4356(99)00203-6
A S Merseburger, M A Kuczyk, Börje Ljungberg, D C Hanbury, P F A Mulders, I C Sinescu, J-J Patard, Guidelines on Renal Cell Carcinoma European Association of Urology. pp. 1- 26 ,(2007)
Cora N. Sternberg, Alan Yagoda, Howard I. Scher, Robin C. Watson, Nancy Geller, Harry W. Herr, Michael J. Morse, Pramod C. Sogani, E. Darracott Vaughan, Neil Bander, Lora Weiselberg, Kim Rosado, Tracy Smart, Shiow-Yun Lin, Darryl Penenberg, William R. Fair, Willet F. Whitmore, Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse Cancer. ,vol. 64, pp. 2448- 2458 ,(1989) , 10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7
Cora N. Sternberg, Nicholas J. Vogelzang, Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Critical Reviews in Oncology Hematology. ,vol. 46, pp. 105- 115 ,(2003) , 10.1016/S1040-8428(03)00068-4
Claus Rödel, Gerhard G. Grabenbauer, Reinhard Kühn, Thomas Papadopoulos, Jürgen Dunst, Martin Meyer, Karl M. Schrott, Rolf Sauer, Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results Journal of Clinical Oncology. ,vol. 20, pp. 3061- 3071 ,(2002) , 10.1200/JCO.2002.11.027
William K. Oh, Miah-Hiang Tay, Jiaoti Huang, Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer. ,vol. 109, pp. 477- 486 ,(2007) , 10.1002/CNCR.22439
John P. Stein, Donald G. Skinner, Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World Journal of Urology. ,vol. 24, pp. 296- 304 ,(2006) , 10.1007/S00345-006-0061-7
Bernard Escudier, Tim Eisen, Walter M Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Negrier, Christine Chevreau, Ewa Solska, Apurva A Desai, Frédéric Rolland, Tomasz Demkow, Thomas E Hutson, Martin Gore, Scott Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M Bukowski, None, Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 125- 134 ,(2007) , 10.1056/NEJMOA060655
Richard J. Sylvester, Adrian P.M. van der Meijden, Willem Oosterlinck, J. Alfred Witjes, Christian Bouffioux, Louis Denis, Donald W.W. Newling, Karlheinz Kurth, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology. ,vol. 49, pp. 466- 477 ,(2006) , 10.1016/J.EURURO.2005.12.031